Can a PET scan tell if immunotherapy will work for melanoma?
NCT ID NCT03356470
First seen Jan 30, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This small pilot study tested whether special PET scans could predict how well melanoma patients respond to immunotherapy drugs like pembrolizumab or nivolumab. Five people with stage IV melanoma received PET scans and tumor biopsies before and after starting treatment. The goal was to find imaging markers that show immune system activation, which might help doctors personalize cancer care in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
F-FDG PET/CT and F-FLT PET/CT imaging
What this could lead to
If successful, this could help doctors predict which melanoma patients will respond to immunotherapy, avoiding unnecessary treatments.
What could go wrong
This is a very small pilot study with only 5 participants, so results may not apply to all patients. It is designed to gather information, not to test a new treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.